🏛️ Verified NIH Record • Updated 2025-10-29
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma (NCT04803877)
SARC038: A Phase 2 Study of Regorafenib in Combination With Nivolumab in Patients With Refractory or Recurrent Osteosarcoma
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Sarcoma Alliance for Research through Collaboration
🩺 Plain-English Summary (8th-Grade Level)
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital of Los Angeles — Los Angeles, California
Age range: 5 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Children's Hospital of Los Angeles — Los Angeles, California
- University of Miami — Miami, Florida
- Johns Hopkins — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Cincinnati Children's — Cincinnati, Ohio
- Oregon Health and Sciences University — Portland, Oregon
- UT Southwestern Medical Center — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteosarcoma
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors — New York, New York
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma — Birmingham, Alabama
- Olaparib With Ceralasertib in Recurrent Osteosarcoma — San Francisco, California
- A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma — Seattle, Washington
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma — Houston, Texas
Explore by condition: All Osteosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.